Chikungunya Fever – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Chikungunya Fever – Pipeline Review, H2 2016’, provides an overview of the Chikungunya Fever pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chikungunya Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chikungunya Fever and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


The report provides a snapshot of the global therapeutic landscape of Chikungunya Fever

The report reviews pipeline therapeutics for Chikungunya Fever by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Chikungunya Fever therapeutics and enlists all their major and minor projects

The report assesses Chikungunya Fever therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Chikungunya Fever

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Chikungunya Fever

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Chikungunya Fever pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abivax S.A.

Arbovax, Inc.

Arno Therapeutics, Inc.

Bharat Biotech International Limited

Ennaid Therapeutics, LLC

Etubics Corporation

Hawaii Biotech, Inc.

HSRx Group

Indian Immunologicals Limited

Inovio Pharmaceuticals, Inc.

Integral Molecular, Inc.

Integrated BioTherapeutics, Inc.

Merck & Co., Inc.

Nanotherapeutics, Inc.

Profectus BioSciences, Inc.

Takeda Pharmaceutical Company Limited

Themis Bioscience GmbH

Valneva SE

Vaxart, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Chikungunya Fever Overview 10

Therapeutics Development 11

Pipeline Products for Chikungunya Fever - Overview 11

Pipeline Products for Chikungunya Fever - Comparative Analysis 12

Chikungunya Fever - Therapeutics under Development by Companies 13

Chikungunya Fever - Therapeutics under Investigation by Universities/Institutes 15

Chikungunya Fever - Pipeline Products Glance 16

Clinical Stage Products 16

Early Stage Products 17

Chikungunya Fever - Products under Development by Companies 18

Chikungunya Fever - Products under Investigation by Universities/Institutes 19

Chikungunya Fever - Companies Involved in Therapeutics Development 20

Abivax S.A. 20

Arbovax, Inc. 21

Arno Therapeutics, Inc. 22

Bharat Biotech International Limited 23

Ennaid Therapeutics, LLC 24

Etubics Corporation 25

Hawaii Biotech, Inc. 26

HSRx Group 27

Indian Immunologicals Limited 28

Inovio Pharmaceuticals, Inc. 29

Integral Molecular, Inc. 30

Integrated BioTherapeutics, Inc. 31

Merck & Co., Inc. 32

Nanotherapeutics, Inc. 33

Profectus BioSciences, Inc. 34

Takeda Pharmaceutical Company Limited 35

Themis Bioscience GmbH 36

Valneva SE 37

Vaxart, Inc. 38

Chikungunya Fever - Therapeutics Assessment 39

Assessment by Monotherapy Products 39

Assessment by Target 40

Assessment by Mechanism of Action 42

Assessment by Route of Administration 44

Assessment by Molecule Type 46

Drug Profiles 48

ABX-1089 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

ABX-1091 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

ABX-311 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Antibody for Chikungunya - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

AR-12 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

chikungunya (viral like particles) vaccine - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

chikungunya vaccine - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

chikungunya vaccine - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

chikungunya vaccine - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

chikungunya vaccine - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

chikungunya vaccine - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

chikungunya vaccine - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

chikungunya vaccine - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

chikungunya vaccine - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

chikungunya vaccine - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

chikungunya vaccine - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

chikungunya vaccine - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

chikungunya vaccine - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

chikungunya vaccine - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

chikungunya vaccine - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

chikungunya vaccine - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

chikungunya vaccine - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

DEF-201 - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

HSRx-431 - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

IMCKV-063 - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

Monoclonal Antibodies for Chikungunya - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

Monoclonal Antibodies for Equine Encephalitis and Chikungunya - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

Monoclonal Antibodies to Inhibit CHIKV E2 for Chikungunya - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

Monoclonal Antibodies to Target Viral E1 and E2 Proteins for Chikungunya and Ross River Virus Fever - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

Monoclonal Antibody for Chikungunya - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

MV-CHIK - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

Peptides for Infectious Diseases - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

Small Molecule to Inhibit NS2 and NS3 for Chikungunya - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

Small Molecules for Chikungunya - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

Synthetic Peptides for Chikungunya - Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

Tatbeclin-1 - Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

Chikungunya Fever - Dormant Projects 89

Chikungunya Fever - Product Development Milestones 90

Featured News & Press Releases 90

Aug 30, 2016: Hawaii Biotech Awarded Grant To Develop Chikungunya Virus Vaccine 90

Aug 25, 2016: Leading Chikungunya Vaccine in Clinical Trial Phase 2 91

Mar 22, 2016: Inovio’s DNA-based Monoclonal Antibody and DNA Vaccine Provide 100% Protection Against Lethal Chikungunya Virus Challenge in Preclinical Study 91

Sep 19, 2015: Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs 93

Mar 02, 2015: Themis Bioscience’s Chikungunya Vaccine Study Results Published in The Lancet Infectious Diseases 94

Dec 10, 2014: Integral Molecular identifies potent inhibitory antibodies against Chikungunya virus 95

Nov 20, 2014: Themis Bioscience’s Vaccine Against Chikunguya Successful In Phase 1 96

Jun 12, 2014: Threat of Emerging Virus can be Stopped: Interim results of First Clinical Trial of Themis Bioscience's Vaccine Candidate Against Chikungunya Fever Prove Successful 97

Mar 27, 2013: Themis Bioscience Plans To Initiate Phase I Study Of Chikungunya Fever Vaccine Candidate 97

Aug 15, 2011: Inviragen And University of Texas Medical Branch Receive Funding For Development Of Chikungunya Virus Vaccine 98

Nov 04, 2010: Novel Recombinant Chikungunya Virus Vaccine Shown To Be Safe And Effective In Multiple Animal Models 98

Nov 02, 2010: Inviragen Receives Two Therapeutic Discovery Project Grants For Vaccine Development 99

Appendix 100

Methodology 100

Coverage 100

Secondary Research 100

Primary Research 100

Expert Panel Validation 100

Contact Us 100

Disclaimer 101

List of Tables

List of Tables

Number of Products under Development for Chikungunya Fever, H2 2016 11

Number of Products under Development for Chikungunya Fever – Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 14

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Development, H2 2016 17

Products under Development by Companies, H2 2016 18

Products under Investigation by Universities/Institutes, H2 2016 19

Chikungunya Fever – Pipeline by Abivax S.A., H2 2016 20

Chikungunya Fever – Pipeline by Arbovax, Inc., H2 2016 21

Chikungunya Fever – Pipeline by Arno Therapeutics, Inc., H2 2016 22

Chikungunya Fever – Pipeline by Bharat Biotech International Limited, H2 2016 23

Chikungunya Fever – Pipeline by Ennaid Therapeutics, LLC, H2 2016 24

Chikungunya Fever – Pipeline by Etubics Corporation, H2 2016 25

Chikungunya Fever – Pipeline by Hawaii Biotech, Inc., H2 2016 26

Chikungunya Fever – Pipeline by HSRx Group, H2 2016 27

Chikungunya Fever – Pipeline by Indian Immunologicals Limited, H2 2016 28

Chikungunya Fever – Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 29

Chikungunya Fever – Pipeline by Integral Molecular, Inc., H2 2016 30

Chikungunya Fever – Pipeline by Integrated BioTherapeutics, Inc., H2 2016 31

Chikungunya Fever – Pipeline by Merck & Co., Inc., H2 2016 32

Chikungunya Fever – Pipeline by Nanotherapeutics, Inc., H2 2016 33

Chikungunya Fever – Pipeline by Profectus BioSciences, Inc., H2 2016 34

Chikungunya Fever – Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 35

Chikungunya Fever – Pipeline by Themis Bioscience GmbH, H2 2016 36

Chikungunya Fever – Pipeline by Valneva SE, H2 2016 37

Chikungunya Fever – Pipeline by Vaxart, Inc., H2 2016 38

Assessment by Monotherapy Products, H2 2016 39

Number of Products by Stage and Target, H2 2016 41

Number of Products by Stage and Mechanism of Action, H2 2016 43

Number of Products by Stage and Route of Administration, H2 2016 45

Number of Products by Stage and Molecule Type, H2 2016 47

Chikungunya Fever – Dormant Projects, H2 2016 89

List of Figures

List of Figures

Number of Products under Development for Chikungunya Fever, H2 2016 11

Number of Products under Development for Chikungunya Fever – Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Products, H2 2016 17

Assessment by Monotherapy Products, H2 2016 39

Number of Products by Top 10 Targets, H2 2016 40

Number of Products by Stage and Top 10 Targets, H2 2016 40

Number of Products by Top 10 Mechanism of Actions, H2 2016 42

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 42

Number of Products by Routes of Administration, H2 2016 44

Number of Products by Stage and Routes of Administration, H2 2016 44

Number of Products by Top 10 Molecule Types, H2 2016 46

Number of Products by Stage and Top 10 Molecule Types, H2 2016 46


Discounts available for multiple purchases.
+44 20 7947 2745

Saved reports